Clinical Trial Update: Long Term Safety of Biphasic Insulin Aspart 30 in Juveniles With Type 1 Diabetes [Phase 3]

View source ↗

Summary

An update on the long-term safety results of Biphasic Insulin Aspart 30 in children with Type 1 diabetes from a Phase 3 trial.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 1 Diabetes Mellitus

Drugs mentioned

• Biphasic insulin aspart 30 (insulin aspart, biphasic 30/70)

Snippet

Sponsor: Novo Nordisk A/S | Conditions: Diabetes, Diabetes Mellitus, Type 1 | Phase 3 | Status: COMPLETED